Obviously, there is a great need for the creation of clinically applicable inhibitors of HSF1 activation, which would enable the opposement of the cancer stemness development and sensitization of CSCs to inhibitors of HSP90 chaperone activity. Here, HSP90AB1 is linked to cancer.